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Given the recent report of a false-positive result in the Platelia Aspergillus enzyme immunoassay in a patient
with cryptococcosis and in yeast extracts and purified galactoxylomannan of Cryptococcus neoformans, we
evaluated culture extracts, purified polysaccharides, clinical specimens, and specimens from animals following
experimental infection. Our results revealed no cross-reactions.
Galactomannans (GalMs) are complex polysaccharides com-
posed of D-galactose and D-mannose. Alkaline-extracted GalMs
from Aspergillus fumigatus contain a core of (136)--D-mannopy-
ranosyl residues, with (135)-linked -galactofuranosyl units.
The pathogenic fungus Cryptococcus neoformans also contains
complex capsular polysaccharides composed of glucuronoxylo-
mannan (GXM) and galactoxylomannans (GalXM). GXM
makes up about 90% of the capsular mass and is a polymer of up
to six different repeating units that consist mostly of a linear
(133)-mannan trisaccharide with side groups consisting of
(132)-glucopyranosyluronic acid and (132)- and (134)-
xylopyranosyl (2, 6). Additionally, the mannan backbone of GXM
is modified by acetyl groups.
GalXM constitutes about 7% of the capsular mass (2) and
has an (136) galactan backbone containing four potential
short oligosaccharide branch structures. The branches are 3-O-
linked to the backbone and consist of an (133)-Man,
(134)-Man, -galactosidase trisaccharide with variable
amounts of (132)- or (133)-xylose side groups (Fig. 1) (2).
The GalXM backbone consists of galactopyranose and a small
amount of galactofuranose (11), unlike GXM, which contains
only mannopyranose (2). A recent study showed that GalXM
was significantly smaller than GXM (1.7  106 Da), with an
average mass of 1  105 Da (6). Since GalXM has a smaller
molecular mass, this implies that GalXM is the most numerous
polysaccharide in the capsule on a molar basis, since there are
2 to 3.5 mol of GalXM for each mole of GXM. However, the
often assumed conclusion that GXM was the most abundant
molecule was based on the total amount of material that was
recovered from the culture supernatant. These capsular com-
ponents are shed into culture media, and GXM is found in
body fluids of patients, assisting in the diagnosis of cryptococ-
cosis. However, whether GalXM is present in body fluids is
unknown, as there is no diagnostic test available for its detec-
tion.
The cell wall GalM of Aspergillus spp. is likewise shed into
culture media and body fluids of patients with aspergillosis,
and it is the target of the Platelia Aspergillus enzyme immuno-
assay (EIA). (135)-Galactofuranosyl side chains are the an-
tigenic sites recognized by the monoclonal antibody used in the
Platelia Aspergillus EIA (8).
Recently, the Platelia Aspergillus EIA was noted to be pos-
itive in a patient with cryptococcal meningitis (4). In that case,
however, the patient was also receiving amoxicillin-clavu-
lanate, a drug associated with false-positive results in the Plate-
lia Aspergillus EIA. GalXM at concentrations of 100 ng/ml or
higher also gave positive results in the Platelia Aspergillus EIA.
GXM, however, the target of the cryptococcal latex agglutina-
tion (LA) test, was negative in the Platelia Aspergillus EIA. The
investigators also demonstrated that C. neoformans yeast sus-
pensions were positive in the Platelia Aspergillus EIA. Cross-
reactivity with C. neoformans was not observed in earlier stud-
ies of the Platelia Aspergillus EIA (9) or the monoclonal
antibodies used in that assay (8). In view of these conflicting
findings, we undertook additional studies of cross-reactivity
with C. neoformans in the Platelia Aspergillus EIA.
Cryptococcal GXM was prepared from C. neoformans strain
24067 and GalXM and GalXM/mannoprotein from strain
cap67 according to published methods (3, 10, 11). Composi-
tional analysis of GalXM was confirmed by gas chromatogra-
phy/mass spectrometry of the per-O-trimethylsilyl derivatives
of the monosaccharide methyl glycosides produced from the
sample by acidic methanolysis. The analysis revealed the moles
percentages for GalXM’s components were as follows: xylose,
17%; mannose, 28%; and galactose, 55% (10). These numbers
are very similar to the moles percentages in Cherniak’s studies:
xylose, 22%; mannose, 29%; and galactose, 50% (11). Addi-
* Corresponding author. Mailing address: MiraVista Diagnostics,
4444 Decatur Blvd., Suite 300, Indianapolis, IN 46241. Phone: (317)
856-2681. Fax: (317) 856-3685. E-mail: jwheat@miravistalabs.com.
 Published ahead of print on 14 March 2007.
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FIG. 1. Comparison of the structures of the major repeating units of GalM from Aspergillus spp. (13) and GalXM and GXM from C.
neoformans (2). The lack of antigenic cross-reactivity between GalM and GalXM in the EIA is apparent in the comparison of these structures. In
comparison to the (135)-galactofuranose side chain epitope linked to an (132)-mannotetraose core by an (136) bond in GalM, GalXM
differs by the absence of (135)-galactofuranose side chains and the presence instead of (133)-xylomannan side chains and an (136)-
galactopyranose core. The lack of structural similarity between the GalM and GXM further reflects the lack of cross-reactivity of the two antigens
in the anti-GalM EIA. Green, galactofuranose or galactopyranose; blue, mannopyranose; red, xylose; gray, glucuronic acid. The asterisk near the
133 galactofuranosylmannopyranose bond indicates that there is currently uncertainty as to whether this linakge is  or  in configuration.
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tionally, we ran a proton nuclear magnetic resonance spectrum
for GalXM without further purification through an ion-ex-
change column as Cherniak had done earlier (11). The analysis
showed that the anomeric region was between 5.4 and 4.3 ppm
in a one-dimensional 1H spectrum recorded at 600 MHz and
56°C and also similar to those reported previously (11). These
antigens were tested in the cryptococcal LA test (Meridian
Bioscience, Cincinnati, OH) and Platelia Aspergillus EIA (Bio-
Rad Laboratories, Redmond, WA). GXM at 10 ng/ml and
GalXM at 100 ng/ml were positive in the cryptococcal LA
test but negative in the Platelia Aspergillus EIA (Table 1). This
finding was verified by testing two different preparations of
GXM from C. neoformans 24067 and three of GalXM, includ-
ing preparations from C. neoformans cap67 grown in Sab-
ouraud’s medium and peptone supplemented with galactose.
We also tested yeast colonies diluted in 1 ml of distilled water
and agitated for 1 min, as described by Dalle et al. (4), and
culture supernatants from C. neoformans (n  4). All were
positive in the cryptococcal LA test (3 to 4 agglutination
tested undiluted) but negative in the Platelia Aspergillus EIA.
The Platelia Aspergillus EIA positive kit control was positive
in the Platelia Aspergillus EIA (3.54 index units) but negative in
the cryptococcal LA test. A partially purified GalM was pre-
pared from A. fumigatus by ethanol precipitation of culture
supernatant (8), and a dilution containing about 1,000 ng/ml of
GalM was prepared by comparison to the Platelia Aspergillus
EIA cutoff control, which contained about 1 ng/ml of GalM.
The A. fumigatus GalM was detected at a concentration of 1
ng/ml in the Platelia Aspergillus EIA but not in the cryptococcal
LA test up to 1,000 ng/ml (Table 1). Furthermore, culture
supernatants and mold colonies diluted in water from strains of
A. fumigatus and A. flavus were positive in the Platelia Aspergil-
lus EIA but negative in the cryptococcal LA test.
Additionally, we tested residual sera or cerebrospinal fluid
from 25 patients that was positive in the cryptococcal LA test.
The cryptococcal LA titer ranged from negative (one sample)
to 1:65,336 (median, 1:1,024), but all were negative in the
Platelia Aspergillus EIA. We also tested residual serum speci-
mens from 20 patients that were positive in the Platelia As-
pergillus EIA. The Aspergillus GalM galactomannan index units
(GMI) ranged from 0.5 to 10.4 (median, 1.9), but all were
negative in the cryptococcal LA test (Table 2).
Cross-reactivity was also studied in experimental models of
invasive aspergillosis and cryptococcosis, according to institu-
tional guidelines. BALB/c 6- to 8-week-old female mice (n 
8) from the National Cancer Institute (NCI) were infected
intravenously with 1  104 organisms of C. neoformans strain
24067 (1). The mice were sacrificed 7 days postinfection by
asphyxiation with CO2, and sera and lungs were immediately
harvested, placed in ice-cold phosphate-buffered saline, and
frozen at 70°C. Tissues were placed in 2 ml of F-12 nutrient
medium (Invitrogen Corporation, Carlsbad, CA) supple-
mented with glucose, glutamic acid, cystine, and HEPES and
homogenized in sterile Ten Broeke (Vineland, NJ) grinders.
The undiluted homogenates were positive in the cryptococcal
LA test, with agglutination scores of 3 or 4 for five, 2 for
two, and 1 for one animal. All were negative in the Platelia
Aspergillus EIA.
Pulmonary aspergillosis in New Zealand White rabbits (n 
7) (Hazelton Research Products, Inc., Denver, PA) was estab-
lished by inoculating them intratracheally with A. fumigatus
(NIH isolate 4215; ATCC no. MYA-1163) (7). The studies
were approved by the Animal Care and Use Committee of the
NCI, and the rabbits were housed and monitored in facilities
accredited by AAALAC International according to guidelines
of the Public Health Service Policy for the Care and Use of
Laboratory Animals. The rabbits were euthanized by intrave-
nous administration of pentobarbital (65 mg/kg of body weight
of pentobarbital sodium in the form of 0.5 ml of beuthanasia-D
special euthanasia solution; Schering-Plough Animal Health
Corp., Union, NJ). Undiluted plasma and bronchoalveolar la-
vage (BAL) fluid were positive in the Platelia Aspergillus EIA:
the GMI ranged from 0.8 to 4.2 (median, 2.4) in plasma and 1.5
to 6.8 (median, 6.4) in BAL fluid. All specimens were negative
in the cryptococcal LA test.
Cross-reactions between GXM, GalXM, and Aspergillus
TABLE 1. Sensitivity of detection of purified polysaccharide antigens
Antigen Antigen concn(ng/ml)
GMI by Platelia
Aspergillus EIAa
Result of
Cn LAb
A. fumigatus GalM 1,000 8.28 0
100 5.52 0
10 0.72 0
1 0.37 0
None 0.06 0
C. neoformans GXM 1,000 0.07 3
100 0.08 2
10 0.09 1
1 0.05 0
None 0.06 0
C. neoformans GalXM 1,000 0.17 3
100 0.07 1
10 0.06 0
1 0.05 0
None 0.06 0
C. neoformans GalXM-MP 1,000 0.11 0
100 0.08 0
10 0.09 0
1 0.04 0
None 0.06 0
a A result was considered to be positive if the GMI was greater than 0.5.
b Results are expressed semiquantitatively on a scale from 0 to 5, with results
from 1 to 5 considered to be positive. Cn, C. neoformans.
TABLE 2. Cross-reactivity in clinical specimens and
experimental infection
Specimen source Assay f
No. of specimens
positive for antigen/
no. tested
Aspergillus Cryptococcus
Infected patients Af GalM EIA 20/20a 0/25b
Cn CPS LA 0/20a 24/25b
Mice experimentally infected Af GalM EIA 5/5a 0/8c
with C. neoformans Cn CPS LA 0/5a 8/8c
Rabbits experimentally Af GalM EIA 7/7d 0/8e
infected with A. fumigatus Cn CPS LA 0/7d 8/8e
a Serum.
b Serum or CSF.
c Spleen tissue.
d BAL fluid.
e Lung tissue.
f Af, A. fumigatus; Cn, C. neoformans.
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GalM were not observed in this study. The reasons for the
discrepant findings, compared to those of Dalle et al. (4), are
unknown. The GalXM used in that study was prepared some
years ago (5, 10) and may have changed during storage. Since
the positive result in the Platelia Aspergillus EIA was noted
only at high concentrations of cryptococcal GalXM (100 ng/
ml), low-level contamination with Aspergillus GalM is also pos-
sible. The limit of detection of the Platelia Aspergillus EIA for
Aspergillus GalM is about 0.5 ng/ml, permitting detection of
low-level contamination. Also, subtle differences in methods
for preparation of the GalXM may have contributed to the
discrepant findings. Nevertheless, the biochemical and nuclear
magnetic resonance characteristics of our GalXM were similar
to that prepared by Cherniak et al. (5, 10), which was used in
Dalle’s study (4).
Previous studies had failed to observe cross-reactivity in
culture supernatants from C. neoformans in the Platelia As-
pergillus EIA (8, 9). Furthermore, positive results in the Past-
orex Aspergillus LA test were not detected in plasma from
guinea pigs with cryptococcosis (12).
A biochemical basis for cross-reactivity between cryptococ-
cal GalXM and Aspergillus GalM is not obvious (2, 13). The
structural dissimilarities among GalM, GalXM, and GXM sug-
gest that the likelihood for shared antigenicity may be small
(Fig. 1). Although -galactofuranose, the epitope recognized
by the monoclonal antibody used in the Aspergillus GalM an-
tigen assay (8), is present in small amounts in GalXM (11), it
is unknown if the two are similar antigenically. Thus, we were
unable to confirm the cross-reactivity of C. neoformans GalXM
or culture extracts or false-positive results in specimens from
patients or animals with cryptococcosis in the Platelia Aspergil-
lus EIA.
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